Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Maintenance in Elderly AML
NCT05909293Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Overall Survival at 2 years and Recurrence-Free Survival at 2 years. Started Apr 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05909293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909293.